Holen Sie sich die Stockscreener-App
66.60
1.05%
0.69
Handel nachbörslich:
66.61
0.01
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.91
Offen:
$66.55
24-Stunden-Volumen:
2.14M
Relative Volume:
1.12
Marktkapitalisierung:
$8.20B
Einnahmen:
$88.04M
Nettoeinkommen (Verlust:
$-784.96M
KGV:
-10.19
EPS:
-6.5335
Netto-Cashflow:
$-534.82M
1W Leistung:
+6.75%
1M Leistung:
+7.04%
6M Leistung:
+19.27%
1J Leistung:
+77.60%
1-Tages-Spanne:
$65.95
$67.92
1-Wochen-Bereich:
$61.67
$67.92
52-Wochen-Spanne:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.60 | 8.12B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
165.01 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
CYTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos, Cytokinetics EVP, sells $236k in shares - Investing.com
3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed - Stock Titan
Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004 - Stock Titan
Retail Trends: Is Cytokinetics Incorporated trading at a discount2026 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating - 富途牛牛
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Inc (HAM:KK3A) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Aug Drivers: What are the future prospects of Cytokinetics Incorporated2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Inc Stock Intrinsic Values | HAM:KK3A - GuruFocus
Cytokinetics Inc (HAM:KK3A) Competitors 2026 - GuruFocus
Should you avoid Cytokinetics Incorporated stock right nowQuarterly Risk Review & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK) - Stock Titan
Cytokinetics Inc (HAM:KK3A) Dividend - GuruFocus
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report? - Yahoo Finance
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart.com
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics (STU:KK3A) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
Cytokinetics (CYTK) 10K Form and Latest SEC Filings 2026 - MarketBeat
Cytokinetics Inc (HAM:KK3A) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 By Investing.com - Investing.com Canada
Blum, Cytokinetics CEO, sells $2.2m in shares By Investing.com - Investing.com Canada
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock - MarketBeat
Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 - Investing.com
Cytokinetics Insiders Sold Shares Worth Over $3.6M - TradingView
Cytokinetics (CYTK) CFO share sale covers RSU tax obligations - Stock Titan
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT - GuruFocus
Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics President & CEO Sold Shares Worth Over $2.2M - TradingView
Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes - Stock Titan
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 31 '26 |
Sale |
65.00 |
3,639 |
236,535 |
66,004 |
| Lee Sung | EVP, Chief Financial Officer |
Mar 17 '26 |
Sale |
62.15 |
4,935 |
306,710 |
87,127 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 17 '26 |
Sale |
62.15 |
8,542 |
530,885 |
71,573 |
| Malik Fady Ibraham | EVP Research & Development |
Mar 17 '26 |
Sale |
62.15 |
12,033 |
747,851 |
153,902 |
| Blum Robert I | President & CEO |
Mar 17 '26 |
Sale |
62.15 |
36,601 |
2,274,752 |
430,330 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 18 '26 |
Sale |
62.07 |
1,930 |
119,795 |
78,185 |
1.52%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):